治疗2型糖尿病新药的心血管风险评价指导原则

2019-10-31 国家药品监督管理局药品审评中心(CDE)

治疗2型糖尿病新药的心血管风险评价指导原则

中文标题:

治疗2型糖尿病新药的心血管风险评价指导原则

发布日期:

2019-10-31

简要介绍:

治疗2型糖尿病新药的心血管风险评价指导原则

相关资料下载:
[AttachmentFileName(sort=100, fileName=治疗2型糖尿病新药的心血管风险评价指导原则)] GetToolGuiderByIdResponse(projectId=1, id=83c981c0018180c2, title=治疗2型糖尿病新药的心血管风险评价指导原则, enTitle=, guiderFrom=, authorId=null, author=, summary=治疗2型糖尿病新药的心血管风险评价指导原则, cover=, journalId=null, articlesId=null, associationId=1936, associationName=国家药品监督管理局药品审评中心(CDE), associationIntro=国家药品监督管理局药品审评中心(CDE), copyright=0, guiderPublishedTime=Thu Oct 31 05:43:41 CST 2019, originalUrl=, linkOutUrl=, content=治疗2型糖尿病新药的心血管风险评价指导原则, tagList=[TagDto(tagId=21508, tagName=型糖尿病)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=67, categoryName=研究设计与统计, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指导原则, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2681, appHits=266, showAppHits=3, pcHits=1599, showPcHits=1180, likes=100, shares=4, comments=3, approvalStatus=1, publishedTime=Thu Oct 31 05:43:41 CST 2019, publishedTimeString=2019-10-31, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=fbzhang, createdTime=Thu Oct 31 05:43:41 CST 2019, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 18:06:25 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=治疗2型糖尿病新药的心血管风险评价指导原则)])
治疗2型糖尿病新药的心血管风险评价指导原则
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=917357, encodeId=cc3391e3579e, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210509/b09fbd886f1e4431b94c8ca932de8daf/7a5fb5dcd8164cd6a2ab2c04b8ecc21f.jpg, createdBy=f75f2321812, createdName=黄伟医生, createdTime=Sun Jan 17 10:23:44 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809856, encodeId=e2fb80985688, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 17 21:06:25 CST 2020, time=2020-08-17, status=1, ipAttribution=)]
    2021-01-17 黄伟医生

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=917357, encodeId=cc3391e3579e, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210509/b09fbd886f1e4431b94c8ca932de8daf/7a5fb5dcd8164cd6a2ab2c04b8ecc21f.jpg, createdBy=f75f2321812, createdName=黄伟医生, createdTime=Sun Jan 17 10:23:44 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809856, encodeId=e2fb80985688, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 17 21:06:25 CST 2020, time=2020-08-17, status=1, ipAttribution=)]
    2020-08-17 ms5000002046462755

    0